艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688488 艾迪药业

已收盘 05-27 15:00:00

{"stockData":{"symbol":"688488","market":"SH","secType":"STK","nameCN":"艾迪药业","latestPrice":14.99,"timestamp":1716793200000,"preClose":14.76,"halted":0,"volume":2326632,"delay":0,"floatShares":421000000,"shares":421000000,"eps":-0.2143,"marketStatus":"已收盘","marketStatusCode":5,"change":0.23,"latestTime":"05-27 15:00:00","open":14.9,"high":15.05,"low":14.3,"amount":34035300,"amplitude":0.0508,"askPrice":14.99,"askSize":151,"bidPrice":14.97,"bidSize":121,"shortable":0,"etf":0,"ttmEps":-0.2143,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716859800000},"adr":0,"adjPreClose":14.76,"symbolType":"stock_kcb","openAndCloseTimeList":[[1716773400000,1716780600000],[1716786000000,1716793200000]],"highLimit":16.24,"lowLimit":13.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":420782808,"pbRate":5.66,"roa":"--","roe":"--","epsLYR":-0.18,"committee":-0.29434,"marketValue":6308000000,"floatMarketCap":6308000000,"peRate":-69.948668,"changeRate":0.0156,"turnoverRate":0.0055,"status":0,"afterMarket":{"amount":0,"volume":0,"close":14.99,"buyVolume":0,"sellVolume":0,"time":1716795239505,"indexStatus":"已收盘 05-27 15:30:00","preClose":14.76}},"requestUrl":"/m/hq/s/688488/","defaultTab":"news","newsList":[{"id":"2438801026","title":"艾迪药业获开源证券买入评级，HIV药物市场持续扩容，创新药艾诺米替有望进一步放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2438801026","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2438801026?lang=zh_cn&edition=full","pubTime":"2024-05-27 17:24","pubTimestamp":1716801862,"startTime":"0","endTime":"0","summary":"5月27日，艾迪药业获开源证券买入评级，近一个月艾迪药业获得2份研报关注。开源证券预计，受益于HIV市场持续扩容，2023年公司抗HIV创新药艾诺韦林片和艾诺米替片的销售初步起量，后续有望进一步放量。同时，公司已于2023年11月向国家药品监督管理局药品审评中心递交艾诺韦林片和艾诺米替片新适应症（针对经治HIV-1感染者）上市许可申请并获受理。研报认为，全球及中国总HIV感染者人数仍处于增长阶段，国家免费抗HIV药物目录更新较慢，医保+自费的抗HIV药物市场规模逐年扩大，为新进入医保目录的HIV药物提供新机遇。风险提示：行业政策变化、HIV新药销售不达预期及竞争格局变动的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405271724249568112b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405271724249568112b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2438371805","title":"开源证券：给予艾迪药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2438371805","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2438371805?lang=zh_cn&edition=full","pubTime":"2024-05-27 16:50","pubTimestamp":1716799835,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意近期对艾迪药业进行研究并发布了研究报告《公司首次覆盖报告：HIV药物市场持续扩容，创新药艾诺米替有望进一步放量》，本报告对艾迪药业给出买入评级，当前股价为14.99元。截至2022年，我国报告存活艾滋病感染者122.3万。复方制剂艾诺米替片于2022年12月获批上市并于2023年底纳入医保。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为20.11。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052700018841.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2437472362","title":"独家药品概念盘中拉升，艾迪药业涨2.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437472362","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2437472362?lang=zh_cn&edition=full","pubTime":"2024-05-24 09:43","pubTimestamp":1716514984,"startTime":"0","endTime":"0","summary":"05月24日，独家药品概念盘中拉升，截至09点43分，独家药品概念整体指数上涨0.60%，报875.730点。从个股上来看，该概念的成分股中，艾迪药业涨2.02%，上海医药、舒泰神、甘李药业涨幅居前。从资金上来看，截止发稿，独家药品概念概念主力净流入为-1336.87万，其中甘李药业受到资金热捧，主力净流入866.27万；拉长时间线来看，该板块近20日主力资金净流入-32.02亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524094304941e9cf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524094304941e9cf9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437833177","title":"艾迪药业05月23日主力资金流入395万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2437833177","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2437833177?lang=zh_cn&edition=full","pubTime":"2024-05-23 15:19","pubTimestamp":1716448756,"startTime":"0","endTime":"0","summary":"05月23日, 艾迪药业股价涨1.16%，报收14.88元，成交金额2654万元，换手率0.43%，振幅3.74%，量比0.67。艾迪药业今日主力资金净流入395万元，连续3日净流入，上一交易日主力净流入205万元，今日环比增加92.68%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为56.25%，平均涨幅为2.49%。该股近5个交易日下跌4.43%，主力资金累计净流入711万元；近20日主力资金累计净流入2446万元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052315384395525997&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052315384395525997&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437201815","title":"医保概念盘中跳水，艾迪药业跌0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437201815","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2437201815?lang=zh_cn&edition=full","pubTime":"2024-05-23 13:46","pubTimestamp":1716443207,"startTime":"0","endTime":"0","summary":"05月23日，医保概念盘中跳水，截至13点46分，医保概念整体指数下跌2.02%，报1096.940点。从个股上来看，该概念的成分股中，艾迪药业跌0.07%，跌幅居前。从资金上来看，截止发稿，医保概念主力净流入为-6.94亿，其中科伦药业受到资金热捧，主力净流入3766.66万；拉长时间线来看，该板块近20日主力资金净流入-84.95亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240523134647af89d46c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240523134647af89d46c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437429632","title":"艾迪药业获得实用新型专利授权：“车载式尿蛋白吸附系统”","url":"https://stock-news.laohu8.com/highlight/detail?id=2437429632","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2437429632?lang=zh_cn&edition=full","pubTime":"2024-05-22 01:57","pubTimestamp":1716314223,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示艾迪药业新获得一项实用新型专利授权，专利名为“车载式尿蛋白吸附系统”，专利申请号为CN202322204640.1，授权日为2024年5月7日。本实用新型提供了一种减少尿液托运、降低人工处理工作量以及可有效提升尿液吸附效率的车载式尿蛋白吸附系统。今年以来艾迪药业新获得专利授权3个，较去年同期增加了50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052200000998.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2436994112","title":"艾迪药业5月17日获融资净买入121万元 环比增加298.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436994112","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436994112?lang=zh_cn&edition=full","pubTime":"2024-05-20 10:00","pubTimestamp":1716170406,"startTime":"0","endTime":"0","summary":"5月17日，艾迪药业获融资净买入121万元，环比上一交易日增加298.46%。其中，融资买入329万元，融资偿还207万元。融券方面，融券卖出0.00万股，当前融券余量为3.03万股。A股市场共有1586股获融资净买入，艾迪药业净买入额排名第399。股市有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520100018877be3f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520100018877be3f1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435152316","title":"北向资金5月14日净卖出艾迪药业11.06万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2435152316","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435152316?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:30","pubTimestamp":1715823043,"startTime":"0","endTime":"0","summary":"5月14日，北向资金减持艾迪药业11.06万股连续3日减持。截止当日收盘，沪股通共持有艾迪药业72.00万股，占流通股0.17%。沪股通减持金额前五个股分别为洛阳钼业、药明康德、工商银行、农业银行、宇通客车。艾迪药业近5个交易日下跌1.85%，沪股通累计减持62.55万股；近20个交易日下跌0.31%，沪股通累计增持11.39万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516093714876e5363&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516093714876e5363&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435761655","title":"艾迪药业(688488)公司简评报告：创新药销售持续改善 进入快速增长阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2435761655","media":"首创证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2435761655?lang=zh_cn&edition=full","pubTime":"2024-05-15 08:49","pubTimestamp":1715734155,"startTime":"0","endTime":"0","summary":"艾诺米替成功进入医保，销售体系调整到位，2024 年蓄势待发。2023 年4 季度，公司HIV 新药实现收入2709 万元，环比出现较大增长；2024 年1 季度，公司HIV 新药实现收入3571.12万元，同比增长76.52%，环比增长31.81%，放量态势明确。我们预计在艾诺米替片放量带动下，2024 年HIV 新药有望保持逐季度环比增长态势。公司公告拟收购南大药业31.161%股权，进一步强化产业链布局，有望增厚收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240515084918876a8365&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240515084918876a8365&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435575488","title":"艾迪药业获首创证券买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2435575488","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435575488?lang=zh_cn&edition=full","pubTime":"2024-05-15 08:45","pubTimestamp":1715733937,"startTime":"0","endTime":"0","summary":"5月15日，艾迪药业获首创证券买入评级，近一个月艾迪药业获得3份研报关注。研报预计在艾诺米替片放量带动下，2024年HIV新药有望保持逐季度环比增长态势。2024年1季度公司人源蛋白粗品业务收入较上年同期减少3821.41万元，公司预计主要是由于客户季节性采购金额波动和尿激酶集采降价影响。公司公告拟收购南大药业31.161%股权，进一步强化产业链布局，有望增厚收益。研报认为，艾迪药业已成功地进行了销售体系的调整，进入了快速增长阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405150845388b095c92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405150845388b095c92&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435963320","title":"艾迪药业：正在筹划以现金方式收购南京南大药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2435963320","media":"证券时报·e公司","top":-1,"share":"https://www.laohu8.com/m/news/2435963320?lang=zh_cn&edition=full","pubTime":"2024-05-13 20:47","pubTimestamp":1715604420,"startTime":"0","endTime":"0","summary":"5月13日晚间，艾迪药业公告，公司正在筹划以现金方式收购南京南大药业有限责任公司31.161%的股权，本次交易尚处于筹划阶段，交易各方尚未签署正式的交易协议，具体交易方案仍在商讨论证中，相关事项尚存在不确定性。2020年7月，艾迪药业公告以自有资金8600万元投资南大药业，受让江苏盛丰持有的19.9646%股权，溢价率为780.17%。交易完成后，艾迪药业成为南大药业第二大股东。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051320475379275e36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051320475379275e36&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435346764","title":"5月13日艾迪药业跌5.46%，中庚小盘价值股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435346764","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435346764?lang=zh_cn&edition=full","pubTime":"2024-05-13 16:21","pubTimestamp":1715588504,"startTime":"0","endTime":"0","summary":"证券之星消息，5月13日艾迪药业跌5.46%，收盘报16.1元，换手率1.41%，成交量5.92万手，成交额9605.07万元。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为中庚小盘价值股票。中庚小盘价值股票目前规模为44.49亿元，最新净值2.2003，较上一交易日下跌0.81%，近一年下跌8.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300014772.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435396871","title":"艾迪药业跌5.34% 近半年4家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2435396871","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2435396871?lang=zh_cn&edition=full","pubTime":"2024-05-13 10:05","pubTimestamp":1715565958,"startTime":"0","endTime":"0","summary":"05月13日，艾迪药业股价大幅下跌，截至10点05分，艾迪药业下跌5.34%，报16.12元/股，成交3029万元，换手率0.43%，振幅6.17%。此外，数据统计显示，近半年内1家券商给予增持建议，4家券商给予买入建议。资金动向截止发稿，艾迪药业获得主力净流出183万元，其中超大单流出76万元，大单流出106万元。北向资金方面，艾迪药业05月10日获得北向资金减持36.62万股，截至05月10日，北向资金当前共持有艾迪药业95.89万股，市值1545万元，持股占流通股比为0.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051310064479273f62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051310064479273f62&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434008086","title":"艾迪药业创近1月新高 近半年4家券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2434008086","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2434008086?lang=zh_cn&edition=full","pubTime":"2024-05-10 11:15","pubTimestamp":1715310949,"startTime":"0","endTime":"0","summary":"05月10日，艾迪药业股价大幅上涨，截至11点15分，艾迪药业上涨5.04%，报17.08元/股，创近1月新高，成交5794万元，换手率0.83%，振幅6.03%。北向资金方面，艾迪药业05月09日获得北向资金增持5.53万股，截至05月09日，北向资金当前共持有艾迪药业132.52万股，市值2263万元，持股占流通股比为0.31%。主营业务及业绩艾迪药业公司主营业务为探索、研发和销售创新性化学药物以及人源蛋白产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405101118397926e9fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405101118397926e9fe&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434020194","title":"【机构调研记录】诺安基金调研百利天恒、艾迪药业等8只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2434020194","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434020194?lang=zh_cn&edition=full","pubTime":"2024-05-10 08:02","pubTimestamp":1715299377,"startTime":"0","endTime":"0","summary":"8）美腾科技 个股亮点：公司是一家以提供工矿业智能装备与系统为主体业务的科技企业诺安基金成立于2003年，截至目前，资产管理规模1786.87亿元，排名35/203；资产管理规模512.6亿元，排名68/203；管理公募基金数104只，排名65/203；旗下公募基金经理32人，排名37/203。旗下最近一年表现最佳的公募基金产品为全球油气能源LOF，最新单位净值为1.07，近一年增长18.95%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000011484.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434102016","title":"【机构调研记录】汇添富基金调研盛邦安全、艾迪药业等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2434102016","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434102016?lang=zh_cn&edition=full","pubTime":"2024-05-10 08:02","pubTimestamp":1715299364,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月9日披露的机构调研信息，汇添富基金近期对4家上市公司进行了调研，相关名单如下：1）盛邦安全 个股亮点：公司为用户提供网络安全基础类产品、业务场景安全类产品、网络空间地图类产品以及网络安全服务，是国内领先的网络安全产品厂商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000011468.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434209060","title":"【机构调研记录】永赢基金调研百利天恒、艾迪药业等7只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2434209060","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434209060?lang=zh_cn&edition=full","pubTime":"2024-05-10 08:02","pubTimestamp":1715299362,"startTime":"0","endTime":"0","summary":"；公司所生产的中间体类产品包括性激素、孕激素等品类永赢基金成立于2013年，截至目前，资产管理规模4227.18亿元，排名24/203；资产管理规模2748.23亿元，排名19/203；管理公募基金数227只，排名26/203；旗下公募基金经理41人，排名24/203。旗下最近一年表现最佳的公募基金产品为永赢股息优选A，最新单位净值为1.32，近一年增长23.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240510080354874e1f7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240510080354874e1f7a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434020120","title":"【机构调研记录】易米基金调研百利天恒、艾迪药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2434020120","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434020120?lang=zh_cn&edition=full","pubTime":"2024-05-10 08:02","pubTimestamp":1715299353,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为易米开鑫价值优选混合A，最新单位净值为1.08，近一年增长4.94%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000011450.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434020111","title":"【机构调研记录】广发基金调研百利天恒、艾迪药业等9只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2434020111","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434020111?lang=zh_cn&edition=full","pubTime":"2024-05-10 08:02","pubTimestamp":1715299348,"startTime":"0","endTime":"0","summary":"6）生益电子 个股亮点：公司具备800G光模块的技术能力，且已经给部分客户供货。；公司产品在汽车领域的应用：发动机控制系统、视频识别系统、智能驾驶辅助系统等；公司的印制电路板是5G通讯中核心元器件7）天岳先进 个股亮点：公司是国内领先的第三代半导体衬底材料生产商，也是半绝缘型碳化硅衬底市场的世界前三。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000011446.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434020971","title":"【机构调研记录】恒生前海基金调研艾迪药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2434020971","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434020971?lang=zh_cn&edition=full","pubTime":"2024-05-10 08:02","pubTimestamp":1715299344,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月9日披露的机构调研信息，恒生前海基金近期对1家上市公司进行了调研，相关名单如下：1）艾迪药业 个股亮点：公司抗艾滋病领域ACC007及其复方制剂ACC008被列入国家十三五“重大新药创制”科技重大专项；公司制药品是三大主流业务之一恒生前海基金成立于2016年，截至目前，资产管理规模129.4亿元，排名126/203；资产管理规模129.4亿元，排名113/203；管理公募基金数41只，排名107/203；旗下公募基金经理6人，排名137/203。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240510080356874e1f7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240510080356874e1f7b&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-20","address":"江苏省扬州市邗江区新甘泉西路69号","stockEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.0403},{"period":"3month","weight":0.1789},{"period":"6month","weight":0.1015},{"period":"1year","weight":0.0933},{"period":"ytd","weight":0.1799}],"companyName":"江苏艾迪药业股份有限公司","boardCode":"AI0041","perCapita":"51084股","boardName":"其他制造业","registeredCapital":"42078万元","compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":0.0145},{"period":"3month","weight":0.028},{"period":"6month","weight":0.0158},{"period":"1year","weight":-0.0351},{"period":"ytd","weight":0.0383}],"survey":"　　江苏艾迪药业股份有限公司主营业务以为HIV为主的抗病毒业务及人源蛋白业务。主要产品有乌司他丁、尤瑞克林、尿激酶等人源蛋白产品以及蜡样芽孢杆菌片、番泻叶颗粒、头孢拉定胶囊等制剂。公司荣获“2023年度扬州民营企业创新20强”、荣登“2022年度扬州市创新型企业50强”名单及“2022年度中国小分子药物企业创新力TOP30排行榜”。","serverTime":1716804712002,"listedPrice":13.99,"stockholders":"8237人(较上一季度减少18.80%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪药业,688488,艾迪药业股票,艾迪药业股票老虎,艾迪药业股票老虎国际,艾迪药业行情,艾迪药业股票行情,艾迪药业股价,艾迪药业股市,艾迪药业股票价格,艾迪药业股票交易,艾迪药业股票购买,艾迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}